Loading…
← CockpitCompetitor Analysis › 600628.SS Shanghai New World Corporation Ltd. Class AOpen in the cockpit ↗

Shanghai New World Corporation Ltd. Class A600628.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Distributors
Momentum leader 82
Mkt cap
$573M
US dollars, full cap
Free float
90%
of shares outstanding
$/day
$15.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-0.1 pp
WACC 5.2%
Hurdle
-3 pp
Req g minus delivered
Close · CNYCN¥5.99
1D-4.2%
1W-8.6%
1M-3.7%
3M-3.4%
6M-10.3%
YTD-23.8%
1Y-20.7%
ATR %4.2%
52w lowhigh38.7% off high

What Shanghai New World does

Employees: 1,144

Shanghai New World at a glance

Size Shanghai New World (600628.SS) is a China Health Care company (Medical Distributors) with a market value of $573M, the 3363rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥5.99 on 18 Nov 2026.

Performance Over six months the shares fell 10.3%, against -2.3% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue fell 1.6% over the last twelve months (peer median +3.9%); the operating margin is 6.0% (peer median 1.9%).

Valuation It trades at 2.1× enterprise value to sales against a peer median of 1.0× (3rd most expensive of 21).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -3 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.1 points below its cost of capital (5.2% WACC).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026Peer median 97600628.SS 90
Six months, rebased to 100: Shanghai New World against the median of its 20 peers (local-currency closes).

Shanghai New World financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.09BCN¥1.09BCN¥1.11BCN¥1.12BCN¥839M
Revenue growth—-2%-1%+34%—
Gross profitCN¥584MCN¥446MCN¥443MCN¥428MCN¥216M
EBITDAn/aCN¥230MCN¥248MCN¥246MCN¥78.2M
Net incomeCN¥58.9MCN¥66.7MCN¥70.0MCN¥31.7M-CN¥52.0M
Free cash flowCN¥68.9MCN¥25.0MCN¥179MCN¥179MCN¥13.1M
Capital expenditureCN¥132MCN¥159MCN¥161MCN¥145MCN¥35.0M
Total debtCN¥475MCN¥542MCN¥572MCN¥598MCN¥638M

Quarterly statements and history in the cockpit →

Shanghai New World competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%2733301370605136603716NEU661700007841043151688366ENTEROARJO-B603368301166DOCM7476600628.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai New World is the large dot.

Fundamentals: revenue growth against valuation

-20%-10%0%+10%0×2×4×2733301370605136603716NEU661700007841043151688366ENTEROARJO-B6033683011667447301584DOCM600628.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai New World is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%2733301370605136NEU0000784104688366ENTERO6033687447301584600628.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shanghai New World is the large dot.

Shanghai New World competitors and peer comparison

How Shanghai New World compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai New World against its 20 peers (data as of 18 Nov 2026)
Measure600628.SSPeer medianRank in peer set
1-month return-3.7%-4.1%11th highest of 21
6-month return-10.3%-2.3%9th lowest of 21
Distance from 52-week high-38.7%-20.5%7th lowest of 21
Revenue growth (TTM)-1.6%+3.9%5th lowest of 21
Operating margin6.0%1.9%5th highest of 21
EV / Sales2.1×1.0×3rd most expensive of 21
Growth the price implies (Req g, 7 yrs)-1.6%0.0%6th least demanding of 16
Growth delivered (Del g)+1.0%+5.7%4th lowest of 16
Hurdle (Req g minus delivered)-2.6 pp-5.3 pp6th most demanding of 16
ROIC minus cost of capital-0.1 pp-0.5 pp10th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Shanghai New World 600628.SSChina$573M-10%-2%6%2.1×-1.6%+1.0%
Arata 2733.TJapan$576M-3%+3%1%0.1×-6.2%+3.8%
GKHT Medical Technology 301370.SZChina$525M-24%-11%1%0.7×13.1%+7.5%
Shanghai Lily & Beauty Cosmetics 605136.SSChina$449M-28%+5%2%1.1×21.1%-18.1%
Thalys Medical Technology 603716.SSChina$446M-33%-43%-18%4.3×n/an/a
Neuca NEU.WAPoland$795M-9%+8%2%0.3×5.3%+8.1%
Gongwin Biopharm 6617.TWOTaiwan$412M+87%+12%-530%288.8×n/an/a
Shenzhen Neptunus Bioengineering 000078.SZChina$411M-48%-22%-1%0.6×58.3%-7.8%
Excelsior Medical 4104.TWTaiwan$404M+5%+11%8%1.4×-1.2%+5.7%
Vital KSK 3151.TJapan$399M-1%+3%0%0.1×4.7%+2.6%
Shanghai Haohai Biological Technology 688366.SSChina$878M-24%-9%-2%1.8×16.9%+13.2%
Entero Healthcare Solutions ENTERO.NSIndia$925M+60%+35%4%1.2×24.7%+29.9%
Arjo ARJO-B.STSweden$974M+42%0%8%1.3×-1.0%+3.9%
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%0.4×-9.7%+6.0%
Shanghai Universal Biotech 301166.SZChina$337M-15%+15%-4%1.0×n/an/a
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%0.3×n/an/a
Nagaileben 7447.TJapan$319M0%+1%21%1.6×-12.7%-0.4%
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%0.5×-2.7%+17.9%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%1.0×n/an/a
AS ONE 7476.TJapan$1.10B+25%+10%12%1.3×0.0%+6.3%
Shinva Medical Instrument 600587.SSChina$1.10B-10%+6%5%0.6×-6.9%+1.2%

Questions

Which companies are Shanghai New World's closest peers?
The cockpit's peer set: Arata (2733.T), GKHT Medical Technology (301370.SZ), Shanghai Lily & Beauty Cosmetics (605136.SS), Thalys Medical Technology (603716.SS), Neuca (NEU.WA), Gongwin Biopharm (6617.TWO), Shenzhen Neptunus Bioengineering (000078.SZ), Excelsior Medical (4104.TW).
Is Shanghai New World expensive compared with its peers?
On ev / sales it trades at 2.1× against a peer median of 1.0×, 3rd most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -3 pp: the price already allows for a slowdown.
How has Shanghai New World stock performed?
Over six months to 18 Nov 2026 the shares returned -10.3% against -2.3% for the median peer; over one year -20.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.